A randomized, double-blind, placebo-controlled phase IIIa study on bIAP, an anti-inflammatory moiety, in patients undergoing combined aortic valve replacement and coronary artery bypass grafting.

Trial Profile

A randomized, double-blind, placebo-controlled phase IIIa study on bIAP, an anti-inflammatory moiety, in patients undergoing combined aortic valve replacement and coronary artery bypass grafting.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Alkaline phosphatase (Primary)
  • Indications Ischaemia; Reperfusion injury
  • Focus Therapeutic Use
  • Acronyms APPIRED II
  • Sponsors Alloksys Life Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top